Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | MLNR | O43193 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23123669 | 0.87 | CXCR3 (0.35) | GAACYP3A4MLNRALDH1A1LMNA | |
| SCHEMBL23122910 | 0.83 | CXCR3 (0.41) | GAAUSP2HSD17B10MAPTALDH1A1 | |
| SCHEMBL23121865 | 0.79 | CYP3A4 (0.37) | CYP3A4 | |
| SCHEMBL23134075 | 0.79 | DDB1 (0.40) | GAACYP3A4MLNRALDH1A1MEN1 | |
| SCHEMBL23121651 | 0.73 | BRD4 (0.40) | CYP3A4LMNASMN1; SMN2EGFRMEN1 | |
| SCHEMBL23122125 | 0.72 | CYP3A4 (0.36) | CYP3A4PKMTSHRSMN1; SMN2 | |
| SCHEMBL23121719 | 0.71 | HSD11B1 (0.38) | CHRM1EGFR | |
| Hydrochloric Acid SCHEMBL23121759 | 0.70 | BCL9 (0.38) | CHRM1EGFR | |
| SCHEMBL23122908 | 0.69 | CXCR3 (0.48) | GAACHRM1KMT2A | |
| SCHEMBL30009398 | 0.69 | CYP3A4 (0.40) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-114641473-A | BRD9 bifunctional degradation agent and use method thereof | 诺华股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | BRD9, BRD2, BRD1 | GAA 1240/4885CYP3A4 1039/4885MLNR 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.